Oncology

January 20, 2021

Deposing the ‘Emperor of All Maladies’ will take a diverse toolkit, not a single moonshot.

January 05, 2021

More oncologists are experiencing burnout due to the loss of face-to-face interactions with patients, according to a report from Cardinal Health Specialty Solutions.

December 29, 2020

Drug and diagnostic approvals and biosimilars news were popular with readers.

December 27, 2020

How the pandemic has accelerated innovation, and how CVS Health is preparing to delivery vaccines for COVID-19.

December 20, 2020

The second mRNA vaccine, which does not need the extreme refrigeration of the Pfizer product, began rolling out of a warehouse in Mississippi early Sunday. Friday brought other late-year approvals in cancer treatment.

December 17, 2020

Prostate cancer is often “indolent,” so it can be monitored and not treated right away.

December 07, 2020

A filing for a bispecific antibody, and more time after a therapy gets more responses.

November 30, 2020

The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.

November 29, 2020

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

November 27, 2020

Public health policies and treatment advances have made a difference.

November 26, 2020

Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.

November 24, 2020

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

November 23, 2020

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

November 20, 2020

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

November 02, 2020

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

November 01, 2020

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

October 25, 2020

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.

October 15, 2020

The Johns Hopkins professor and new MHE editorial advisory board member lauds the effects of the Affordable Care Act but holds out for a program that “gets every human being the healthcare that every human being deserves,” in this second part of a four-part series.

September 30, 2020

This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.

September 25, 2020

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.